SI1799633T1 - Kristalinične oblike hidroklorida (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenola za uporabo kot aktivna sestavina v farmacevtskih sestavkih - Google Patents

Kristalinične oblike hidroklorida (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenola za uporabo kot aktivna sestavina v farmacevtskih sestavkih

Info

Publication number: SI1799633T1
Authority: SI; Slovenia
Prior art keywords: methylpropyl; dimethylamino; ethyl; active ingredient; pharmaceutical compositions
Prior art date: 2004-06-28

Application number

SI200531252T

Other languages

English (en)

Inventor

Andreas Fischer

Helmut Buschmann

Michael Gruss

Dagmar Lischke

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-28

Filing date

2005-06-27

Publication date

2011-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1799633(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-27 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2011-05-31 Publication of SI1799633T1 publication Critical patent/SI1799633T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SI200531252T 2004-06-28 2005-06-27 Kristalinične oblike hidroklorida (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenola za uporabo kot aktivna sestavina v farmacevtskih sestavkih SI1799633T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04015091A EP1612203B1 (en)	2004-06-28	2004-06-28	Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
EP05770026A EP1799633B1 (en)	2004-06-28	2005-06-27	Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride for use as active ingredient in pharmaceutical compositions
PCT/EP2005/006884 WO2006000441A2 (en)	2004-06-28	2005-06-27	Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (1)

Publication Number	Publication Date
SI1799633T1 true SI1799633T1 (sl)	2011-05-31

Family

ID=34925507

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI200430461T SI1612203T1 (sl)	2004-06-28	2004-06-28	Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
SI200531252T SI1799633T1 (sl)	2004-06-28	2005-06-27	Kristalinične oblike hidroklorida (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenola za uporabo kot aktivna sestavina v farmacevtskih sestavkih

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI200430461T SI1612203T1 (sl)	2004-06-28	2004-06-28	Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida

Country Status (27)

Country	Link
US (16)	US20070213405A1 (sl)
EP (2)	EP1612203B1 (sl)
JP (1)	JP4990764B2 (sl)
KR (1)	KR101096501B1 (sl)
CN (1)	CN1997621B (sl)
AR (2)	AR049949A1 (sl)
AT (2)	ATE368639T1 (sl)
AU (1)	AU2005256512B2 (sl)
BR (2)	BR122018014454B8 (sl)
CA (1)	CA2572147C (sl)
CY (2)	CY1106929T1 (sl)
DE (2)	DE602004007905T2 (sl)
DK (2)	DK1612203T3 (sl)
EC (1)	ECSP17046065A (sl)
ES (2)	ES2291780T3 (sl)
HR (1)	HRP20110050T8 (sl)
IL (1)	IL180373A (sl)
MX (1)	MXPA06014741A (sl)
NO (3)	NO338605B1 (sl)
NZ (1)	NZ551605A (sl)
PE (1)	PE20060372A1 (sl)
PL (2)	PL1612203T3 (sl)
PT (2)	PT1612203E (sl)
RU (1)	RU2423345C2 (sl)
SI (2)	SI1612203T1 (sl)
WO (1)	WO2006000441A2 (sl)
ZA (1)	ZA200700774B (sl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
SI1612203T1 (sl) *	2004-06-28	2007-12-31	Gruenenthal Chemie	Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de)	2007-03-07	2008-09-11	Grünenthal GmbH	Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) *	2007-04-23	2008-11-13	Grünenthal GmbH	Tapentadol zur Schmerzbehandlung bei Arthrose
ES2623413T3 (es) *	2007-12-07	2017-07-11	Grünenthal GmbH	Modificaciones cristalinas de (1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol
AU2009207796B2 (en)	2008-01-25	2014-03-27	Grunenthal Gmbh	Pharmaceutical dosage form
KR101690094B1 (ko)	2008-05-09	2016-12-27	그뤼넨탈 게엠베하	분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
US20100272815A1 (en) *	2009-04-28	2010-10-28	Actavis Group Ptc Ehf	Amorphous form of tapentadol hydrochloride
CA2765971C (en)	2009-07-22	2017-08-22	Gruenenthal Gmbh	Hot-melt extruded controlled release dosage form
ES2428938T3 (es)	2009-07-22	2013-11-12	Grünenthal GmbH	Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
US8288592B2 (en) *	2009-09-22	2012-10-16	Actavis Group Ptc Ehf	Solid state forms of tapentadol salts
WO2011138037A2 (de)	2010-05-05	2011-11-10	Ratiopharm Gmbh	Festes tapentadol in nicht-kristalliner form
MX341072B (es) *	2010-07-23	2016-08-05	Grünenthal Gmbh *	Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
PL2611425T3 (pl)	2010-09-02	2014-09-30	Gruenenthal Gmbh	Odporna na ingerencję postać dawki zawierająca polimer anionowy
RU2604676C2 (ru)	2010-09-02	2016-12-10	Грюненталь Гмбх	Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
WO2012051246A1 (en)	2010-10-12	2012-04-19	Ratiopharm Gmbh	Tapentadol hydrobromide and crystalline forms thereof
KR102051800B1 (ko)	2011-03-04	2019-12-04	그뤼넨탈 게엠베하	경구 투여를 위한 타펜타돌의 수성 약제학적 제형
CA2828637C (en)	2011-03-04	2019-06-11	Grunenthal Gmbh	Semisolid aqueous pharmaceutical composition containing tapentadol
KR101970468B1 (ko) *	2011-03-04	2019-04-19	그뤼넨탈 게엠베하	타펜타돌의 비경구 투여
HRP20171458T1 (hr)	2011-07-29	2017-11-17	Grünenthal GmbH	Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
PL2736495T3 (pl)	2011-07-29	2018-01-31	Gruenenthal Gmbh	Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
WO2013111161A2 (en) *	2012-01-10	2013-08-01	Msn Laboratories Limited	Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en)	2012-02-17	2013-08-22	Zentiva, K.S.	A new solid form of tapentadol and a method of its preparation
WO2013127831A1 (en)	2012-02-28	2013-09-06	Grünenthal GmbH	Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
LT2838512T (lt)	2012-04-18	2018-11-12	GrĆ¼nenthal GmbH	Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) *	2012-07-24	2014-07-16	Zentiva, K.S.	Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) *	2012-10-31	2013-11-20	合肥市新星医药化工有限公司	盐酸他喷他多晶型c及其制备方法和应用
JP6445537B2 (ja)	2013-05-29	2018-12-26	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	１個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AR096438A1 (es)	2013-05-29	2015-12-30	Gruenenthal Gmbh	Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
EP2808319A1 (en)	2013-05-31	2014-12-03	Arevipharma GmbH	3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
US10624862B2 (en)	2013-07-12	2020-04-21	Grünenthal GmbH	Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) *	2013-09-04	2015-03-11	Grünenthal GmbH	Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
USD730877S1 (en)	2013-09-06	2015-06-02	Plantronics, Inc.	Communications headset
US9599565B1 (en) *	2013-10-02	2017-03-21	Ondax, Inc.	Identification and analysis of materials and molecular structures
WO2015071248A1 (en)	2013-11-15	2015-05-21	Synthon B.V.	Abuse-proofed extended release pharmaceutical composition comprising tapentadol
JP6480936B2 (ja)	2013-11-26	2019-03-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	クライオミリングによる粉末状医薬組成物の調製
CZ307492B6 (cs)	2014-02-04	2018-10-17	Zentiva, K.S.	Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) *	2014-02-12	2015-08-19	Azad Pharmaceutical Ingredients Ag	Stable polymorph form B of tapentadol hydrochloride
JP2017518980A (ja)	2014-05-12	2017-07-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	タペンタドールを含む、改変防止即時放出カプセル製剤
CN106456550A (zh)	2014-05-26	2017-02-22	格吕伦塔尔有限公司	避免乙醇剂量倾泻的多颗粒
PT3273953T (pt)	2015-03-27	2019-04-01	Gruenenthal Gmbh	Formulação estável para administração parentérica de tapentadol
KR20170139158A (ko)	2015-04-24	2017-12-18	그뤼넨탈 게엠베하	즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
WO2017042325A1 (en)	2015-09-10	2017-03-16	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
WO2017182438A1 (en)	2016-04-19	2017-10-26	Ratiopharm Gmbh	Crystalline tapentadol phosphate
BR112019005439A2 (pt)	2016-09-23	2019-06-18	Gruenenthal Gmbh	formulação estável para administração parenteral de tapentadol
EP3585370A1 (en)	2017-02-23	2020-01-01	Grünenthal GmbH	Tapentadol as local anesthetic
US11492342B2 (en)	2020-11-03	2022-11-08	Landos Biopharma, Inc.	Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4426245A1 (de) *	1994-07-23	1996-02-22	Gruenenthal Gmbh	1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
GEP20022636B (en) *	1996-08-14	2002-02-25	Searle & Co Us	4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
US6906087B2 (en) *	2000-10-31	2005-06-14	Ciba Specialty Chemicals Corpation	Crystalline forms of venlafaxine hydrochloride
US20050176790A1 (en) *	2001-02-28	2005-08-11	Johannes Bartholomaus	Pharmaceutical salts
ES2314092T3 (es) *	2001-09-13	2009-03-16	Kissei Pharmaceutical Co., Ltd.	Cristales de un derivado de hidroxinorefredina.
PE20030527A1 (es) *	2001-10-24	2003-07-26	Gruenenthal Chemie	Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
SI1612203T1 (sl) *	2004-06-28	2007-12-31	Gruenenthal Chemie	Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
ES2623413T3 (es) *	2007-12-07	2017-07-11	Grünenthal GmbH	Modificaciones cristalinas de (1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol

2004
- 2004-06-28 SI SI200430461T patent/SI1612203T1/sl unknown
- 2004-06-28 AT AT04015091T patent/ATE368639T1/de active
- 2004-06-28 PL PL04015091T patent/PL1612203T3/pl unknown
- 2004-06-28 ES ES04015091T patent/ES2291780T3/es not_active Expired - Lifetime
- 2004-06-28 DK DK04015091T patent/DK1612203T3/da active
- 2004-06-28 PT PT04015091T patent/PT1612203E/pt unknown
- 2004-06-28 EP EP04015091A patent/EP1612203B1/en not_active Expired - Lifetime
- 2004-06-28 DE DE602004007905T patent/DE602004007905T2/de not_active Expired - Lifetime
2005
- 2005-06-27 PT PT05770026T patent/PT1799633E/pt unknown
- 2005-06-27 AU AU2005256512A patent/AU2005256512B2/en not_active Expired
- 2005-06-27 WO PCT/EP2005/006884 patent/WO2006000441A2/en not_active Ceased
- 2005-06-27 DK DK05770026.2T patent/DK1799633T3/da active
- 2005-06-27 NZ NZ551605A patent/NZ551605A/en not_active IP Right Cessation
- 2005-06-27 CN CN2005800216611A patent/CN1997621B/zh not_active Expired - Fee Related
- 2005-06-27 MX MXPA06014741A patent/MXPA06014741A/es active IP Right Grant
- 2005-06-27 DE DE602005026031T patent/DE602005026031D1/de not_active Expired - Lifetime
- 2005-06-27 PE PE2005000742A patent/PE20060372A1/es active IP Right Grant
- 2005-06-27 BR BR122018014454A patent/BR122018014454B8/pt active IP Right Grant
- 2005-06-27 BR BRPI0512792-0A patent/BRPI0512792A/pt not_active Application Discontinuation
- 2005-06-27 RU RU2007103297/04A patent/RU2423345C2/ru active
- 2005-06-27 CA CA2572147A patent/CA2572147C/en not_active Expired - Lifetime
- 2005-06-27 KR KR1020077002099A patent/KR101096501B1/ko not_active Expired - Lifetime
- 2005-06-27 EP EP05770026A patent/EP1799633B1/en not_active Expired - Lifetime
- 2005-06-27 JP JP2007518520A patent/JP4990764B2/ja not_active Expired - Lifetime
- 2005-06-27 SI SI200531252T patent/SI1799633T1/sl unknown
- 2005-06-27 PL PL05770026T patent/PL1799633T3/pl unknown
- 2005-06-27 ES ES05770026T patent/ES2359504T3/es not_active Expired - Lifetime
- 2005-06-27 AT AT05770026T patent/ATE496021T1/de active
- 2005-06-27 HR HR20110050T patent/HRP20110050T8/xx unknown
- 2005-06-28 AR ARP050102663A patent/AR049949A1/es not_active Application Discontinuation
2006
- 2006-12-26 IL IL180373A patent/IL180373A/en active IP Right Grant
- 2006-12-28 US US11/646,232 patent/US20070213405A1/en not_active Abandoned
2007
- 2007-01-09 NO NO20070162A patent/NO338605B1/no unknown
- 2007-01-26 ZA ZA200700774A patent/ZA200700774B/xx unknown
- 2007-10-11 CY CY20071101312T patent/CY1106929T1/el unknown
2008
- 2008-11-20 US US12/274,747 patent/US20090186947A1/en not_active Abandoned
2009
- 2009-12-10 US US12/634,777 patent/US7994364B2/en not_active Expired - Lifetime
2011
- 2011-02-16 CY CY20111100192T patent/CY1111530T1/el unknown
- 2011-06-29 US US13/172,009 patent/US20110294898A1/en not_active Abandoned
2012
- 2012-08-03 US US13/565,867 patent/US20120302643A1/en not_active Abandoned
2013
- 2013-06-21 US US13/923,891 patent/US20140011886A1/en not_active Abandoned
2014
- 2014-06-13 US US14/304,313 patent/US20140296346A1/en not_active Abandoned
2015
- 2015-11-02 US US14/930,337 patent/US20160122287A1/en not_active Abandoned
2016
- 2016-05-30 NO NO20160914A patent/NO341239B1/no unknown
2017
- 2017-02-09 US US15/428,613 patent/US20170166515A1/en not_active Abandoned
- 2017-07-04 NO NO20171103A patent/NO343922B1/no unknown
- 2017-07-17 EC ECIEPI201746065A patent/ECSP17046065A/es unknown
- 2017-10-05 US US15/725,967 patent/US20180029976A1/en not_active Abandoned
2018
- 2018-04-12 US US15/951,838 patent/US20180230082A1/en not_active Abandoned
- 2018-10-26 US US16/172,100 patent/US20190062263A1/en not_active Abandoned
2019
- 2019-09-02 AR ARP190102495A patent/AR116052A2/es not_active Application Discontinuation
- 2019-10-14 US US16/600,884 patent/US20200102261A1/en not_active Abandoned
2020
- 2020-06-23 US US16/909,123 patent/US20200385334A1/en not_active Abandoned
2021
- 2021-03-08 US US17/194,717 patent/US20210261492A1/en not_active Abandoned
2023
- 2023-01-30 US US18/103,410 patent/US20230174458A1/en active Pending

Also Published As

Publication number	Publication date
DE602004007905D1 (de)	2007-09-13
ES2359504T3 (es)	2011-05-24
HRP20110050T8 (en)	2011-03-31
US20140296346A1 (en)	2014-10-02
BR122018014454B8 (pt)	2021-07-27
US20090186947A1 (en)	2009-07-23
PL1799633T3 (pl)	2011-06-30
US20110294898A1 (en)	2011-12-01
CN1997621B (zh)	2011-06-15
CN1997621A (zh)	2007-07-11
US7994364B2 (en)	2011-08-09
NO343922B1 (no)	2019-07-08
DK1799633T3 (da)	2011-03-28
RU2423345C2 (ru)	2011-07-10
ATE368639T1 (de)	2007-08-15
JP2008504326A (ja)	2008-02-14
NO20160914A1 (no)	2007-01-24
EP1799633B1 (en)	2011-01-19
AR116052A2 (es)	2021-03-25
IL180373A0 (en)	2007-06-03
DK1612203T3 (da)	2007-12-03
BR122018014454B1 (pt)	2019-09-03
CY1111530T1 (el)	2015-08-05
HRP20110050T1 (hr)	2011-02-28
KR20070039929A (ko)	2007-04-13
CA2572147C (en)	2012-10-30
AU2005256512A1 (en)	2006-01-05
ECSP17046065A (es)	2018-11-30
US20200102261A1 (en)	2020-04-02
PL1612203T3 (pl)	2007-12-31
US20120302643A1 (en)	2012-11-29
DE602004007905T2 (de)	2008-05-08
ES2291780T3 (es)	2008-03-01
US20200385334A1 (en)	2020-12-10
DE602005026031D1 (de)	2011-03-03
US20180230082A1 (en)	2018-08-16
US20100160447A1 (en)	2010-06-24
US20180029976A1 (en)	2018-02-01
JP4990764B2 (ja)	2012-08-01
US20160122287A1 (en)	2016-05-05
PT1799633E (pt)	2011-03-07
WO2006000441A2 (en)	2006-01-05
KR101096501B1 (ko)	2011-12-20
EP1612203A1 (en)	2006-01-04
NO341239B1 (no)	2017-09-25
AU2005256512B2 (en)	2011-05-19
US20170166515A1 (en)	2017-06-15
NO20171103A1 (no)	2007-01-24
NO338605B1 (no)	2016-09-12
NO20070162L (no)	2007-01-24
PE20060372A1 (es)	2006-05-08
CY1106929T1 (el)	2012-09-26
AR049949A1 (es)	2006-09-20
PT1612203E (pt)	2007-08-20
EP1799633A2 (en)	2007-06-27
EP1612203B1 (en)	2007-08-01
NZ551605A (en)	2010-01-29
RU2007103297A (ru)	2008-08-10
WO2006000441A3 (en)	2006-05-04
US20070213405A1 (en)	2007-09-13
CA2572147A1 (en)	2006-01-05
US20230174458A1 (en)	2023-06-08
US20190062263A1 (en)	2019-02-28
IL180373A (en)	2012-05-31
US20140011886A1 (en)	2014-01-09
US20210261492A1 (en)	2021-08-26
ATE496021T1 (de)	2011-02-15
BRPI0512792A (pt)	2008-04-08
SI1612203T1 (sl)	2007-12-31
MXPA06014741A (es)	2007-02-12
ZA200700774B (en)	2008-09-25

Publication	Publication Date	Title
PL1799633T3 (pl)	2011-06-30	Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu do stosowania jako składnik aktywny w kompozycjach farmaceutycznych
DK1786403T3 (da)	2013-08-19	Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
TWI366460B (en)	2012-06-21	Cannabinoid active pharmaceutical ingredient for improved dosage forms
ZA200705750B (en)	2008-11-26	Compositions and methods for stabilizing active pharmaceutical ingredients
PL2054411T3 (pl)	2015-02-27	Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
MY159203A (en)	2016-12-30	Solid preparation comprising alogliptin and metformin hydrochloride
EA017091B9 (ru)	2014-10-30	Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
IL206197A (en)	2015-03-31	Crystalline forms of the compound (r1, r2) –3– (3– dimethylamino – 1 – ethyl – 2 – methyl-profile) –phenol processes for their preparation, pharmaceutical compositions containing them, and their use in the preparation of pain treatment compositions
WO2007002597A3 (en)	2009-04-23	Modified-release formulations of a bupropion salt
PL1802197T3 (pl)	2018-07-31	Grzybobójcze kombinacje substancji czynnych
EP2279732A3 (en)	2012-04-25	Compounds and compositions for delivering active agents
WO2007102127A3 (en)	2008-04-03	New amines
ZA200709788B (en)	2008-08-27	Cannabinold active pharmaceutical ingredient for Improved dosage forms
EP1861358A4 (en)	2011-08-31	NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
PL1932522T3 (pl)	2012-09-28	Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
IL177402A0 (en)	2006-12-10	Composition for oral administration of tamsulosin hydrochloride
WO2007099410A3 (en)	2008-04-17	Formulations of fispemifene
WO2007035718A3 (en)	2009-06-18	Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid
WO2007083096A3 (en)	2007-11-01	N- (2, 3-difluorophenyl) -2- [4- ( {7-methoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazoli n-4-yl}amino) -lh-pyrazol-1-yl] acetamide and n- (2, 3 -d i fluoro phenyl) -2- [4- ( {7-ethoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazolin
WO2005121074A3 (en)	2006-05-18	Processes for the preparation of sertraline hydrochloride
WO2007022532A3 (en)	2009-04-23	Cyclopropyl compounds and compositions for delivering active agents
HK1116670A (en)	2009-01-02	Compositions and methods for stabilizing active pharmaceutical ingredients
MX2010002358A (es)	2010-03-22	Formulacion farmaceutica para liberacion prolongada.